PT1549770E - Métodos para prever aumentos de colesterol durante terapia imunossupressora - Google Patents

Métodos para prever aumentos de colesterol durante terapia imunossupressora Download PDF

Info

Publication number
PT1549770E
PT1549770E PT03779798T PT03779798T PT1549770E PT 1549770 E PT1549770 E PT 1549770E PT 03779798 T PT03779798 T PT 03779798T PT 03779798 T PT03779798 T PT 03779798T PT 1549770 E PT1549770 E PT 1549770E
Authority
PT
Portugal
Prior art keywords
methods
predict
immunosuppressant therapy
elevations during
cholesterol
Prior art date
Application number
PT03779798T
Other languages
English (en)
Portuguese (pt)
Inventor
Sridhar Kudaravalli
Mihael Hristos Polymeropoulos
Rosarelis Torres
Curt Douglas Wolfgang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1549770(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1549770E publication Critical patent/PT1549770E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT03779798T 2002-09-30 2003-09-29 Métodos para prever aumentos de colesterol durante terapia imunossupressora PT1549770E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41512302P 2002-09-30 2002-09-30

Publications (1)

Publication Number Publication Date
PT1549770E true PT1549770E (pt) 2008-06-24

Family

ID=32043422

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03779798T PT1549770E (pt) 2002-09-30 2003-09-29 Métodos para prever aumentos de colesterol durante terapia imunossupressora

Country Status (13)

Country Link
US (2) US7732134B2 (enExample)
EP (1) EP1549770B1 (enExample)
JP (1) JP4575775B2 (enExample)
CN (1) CN100453650C (enExample)
AT (1) ATE389034T1 (enExample)
AU (1) AU2003287955B2 (enExample)
BR (1) BR0314552A (enExample)
CA (1) CA2500979A1 (enExample)
DE (1) DE60319719T2 (enExample)
ES (1) ES2302959T3 (enExample)
IL (1) IL167639A (enExample)
PT (1) PT1549770E (enExample)
WO (1) WO2004029618A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007147600A (ru) * 2005-05-31 2009-07-20 Новартис АГ (CH) КОМБИНАЦИЯ ИНГИБИТОРОВ ГИДРОКСИ-МЕТИЛГЛУТАРИЛ-КОЭНЗИМ-А-РЕДУКТАЗЫ (ГМГ-КоА-РЕДУКТАЗЫ) И ИНГИБИТОРОВ МИШЕНИ РАПАМИЦИНА МЛЕКОПИТАЮЩИХ (МРМ)
JP2013509883A (ja) 2009-11-06 2013-03-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 臓器移植患者における移植片拒絶反応の非侵襲的診断方法
CA2793170C (en) * 2010-03-15 2018-04-17 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
EP1463745A4 (en) * 2001-11-19 2007-11-07 Interleukin Genetics Inc FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 SITE AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES

Also Published As

Publication number Publication date
CN100453650C (zh) 2009-01-21
WO2004029618A2 (en) 2004-04-08
US20060246439A1 (en) 2006-11-02
BR0314552A (pt) 2005-08-09
JP4575775B2 (ja) 2010-11-04
ES2302959T3 (es) 2008-08-01
ATE389034T1 (de) 2008-03-15
AU2003287955B9 (en) 2004-04-19
WO2004029618A3 (en) 2004-06-17
CA2500979A1 (en) 2004-04-08
EP1549770B1 (en) 2008-03-12
US7732134B2 (en) 2010-06-08
IL167639A (en) 2011-10-31
HK1084445A1 (zh) 2006-07-28
AU2003287955B2 (en) 2007-06-21
DE60319719T2 (de) 2009-03-12
EP1549770A2 (en) 2005-07-06
US20100184798A1 (en) 2010-07-22
JP2006500930A (ja) 2006-01-12
DE60319719D1 (de) 2008-04-24
CN1685062A (zh) 2005-10-19
AU2003287955A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
MY169308A (en) Treatment of tnf? related disorders
TNSN05300A1 (en) Treatment with anti-vegf antibodies
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
UA91521C2 (ru) Композиции, содержащие липазу, протеазу и амилазу, предназначенные для лечения недостаточности поджелудочной железы
WO2004019884A3 (en) Agents and methods for enhancing bone formation
PT1427409E (pt) Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
TW200508233A (en) Chk-1 inhibitors
TW200630089A (en) Treatment methods
PT1549770E (pt) Métodos para prever aumentos de colesterol durante terapia imunossupressora
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
WO2006004774A3 (en) Laulimalide analogues as therapeutic agents
WO2003063784A3 (en) MOLECULES THAT MODULATE GαQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE
AU2003229876A1 (en) Tumour associated antigens
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
AU2003250248A1 (en) Process and auxiliaries for the treatment of organically tanned leather
WO2004103316A3 (en) Orp9, a novel therapeutic target for increasing hdl levels
UA70045A (en) Method for treatment in pathologic preliminary period
WO2004026102A3 (en) Treatment of schizophrenia
EP1184465A3 (en) Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms